Optiver Holding’s BioMarin Pharmaceuticals BMRN Stock Holding History

Optiver Holding’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-98	Closed	-$9K	–	540
2021 Q4	$9K	Buy	+98	New	+$8.09K	﹤0.01%	707

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Optiver Holding's BMRN Position: Q1 2022 in Review

Optiver Holding sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2022, closing a stake of 98 shares — an estimated $9K sold.

Optiver Holding first reported a position in BMRN in Q4 2021 and held it in 1 quarter. The position peaked at $9K in Q4 2021. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2022.

Optiver Holding reported no remaining BioMarin Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Optiver Holding sold 98 BioMarin Pharmaceuticals shares in Q1 2022, an estimated $9K.
Optiver Holding first reported a position in BioMarin Pharmaceuticals in Q4 2021 and held it in 1 quarter.
Optiver Holding's BioMarin Pharmaceuticals position peaked at $9K in Q4 2021.
560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2022.

Based on Optiver Holding's 13F filing for Q1 2022, filed 16 May 2022.